1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Pulmonary Drugs Market, by Indication
6.1. Introduction
6.2. Allergic Rhinitis
6.3. Asthma
6.4. COPD (Chronic Obstructive Pulmonary Disease)
6.5. Cystic Fibrosis
6.6. Others
6.7. Pulmonary Arterial Hypertension

7. Pulmonary Drugs Market, by Drug Class
7.1. Introduction
7.2. Anti-cholinergic Agents
7.3. Anti-leukotrienes
7.4. Antihistamines
7.5. Beta-2 Agonists
7.6. Combination Drugs
7.7. Monoclonal Antibodies
7.8. Oral and Inhaled Corticosteroids
7.9. Others

8. California Pulmonary Drugs Market

9. Florida Pulmonary Drugs Market

10. Illinois Pulmonary Drugs Market

11. New York Pulmonary Drugs Market

12. Ohio Pulmonary Drugs Market

13. Pennsylvania Pulmonary Drugs Market

14. Texas Pulmonary Drugs Market

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. AstraZeneca plc
16.2. Bayer AG
16.3. Boehringer Ingelheim GmbH
16.4. Bristol-Myers Squibb Co.
16.5. F.Hoffmann-La Roche Ltd.
16.6. Gilead Sciences Inc.
16.7. GlaxoSmithKline plc
16.8. Mallinckrodt Pharmaceuticals
16.9. Merck & Co.
16.10. Novartis International AG
16.11. Pfizer Inc.
16.12. Sanofi S.A
16.13. Teva Pharmaceutical Industries Ltd.
16.14. Vertex Pharmaceuticals Inc

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES PULMONARY DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES PULMONARY DRUGS MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2020 VS 2027 (USD BILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2027
FIGURE 6. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2027 (USD BILLION)
FIGURE 7. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 8. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ASTHMA, 2018-2027 (USD BILLION)
FIGURE 9. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 10. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), 2018-2027 (USD BILLION)
FIGURE 11. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 12. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, 2018-2027 (USD BILLION)
FIGURE 13. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 14. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
FIGURE 15. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 16. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, 2018-2027 (USD BILLION)
FIGURE 17. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2027 (%)
FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2027 (USD BILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 21. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, 2018-2027 (USD BILLION)
FIGURE 22. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 23. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, 2018-2027 (USD BILLION)
FIGURE 24. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 25. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2027 (USD BILLION)
FIGURE 26. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 27. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2027 (USD BILLION)
FIGURE 28. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 29. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2027 (USD BILLION)
FIGURE 30. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 31. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 32. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 33. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, 2018-2027 (USD BILLION)
FIGURE 34. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 35. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
FIGURE 36. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY STATE, 2020 VS 2027 (USD BILLION)
FIGURE 37. UNITED STATES PULMONARY DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 38. UNITED STATES PULMONARY DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 39. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES PULMONARY DRUGS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES PULMONARY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 4. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY STATE, 2018-2027 (USD BILLION)
TABLE 5. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY STATE, 2018-2027 (USD BILLION)
TABLE 6. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), BY STATE, 2018-2027 (USD BILLION)
TABLE 7. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY STATE, 2018-2027 (USD BILLION)
TABLE 8. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY STATE, 2018-2027 (USD BILLION)
TABLE 9. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY STATE, 2018-2027 (USD BILLION)
TABLE 10. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 11. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY STATE, 2018-2027 (USD BILLION)
TABLE 12. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY STATE, 2018-2027 (USD BILLION)
TABLE 13. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY STATE, 2018-2027 (USD BILLION)
TABLE 14. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY STATE, 2018-2027 (USD BILLION)
TABLE 15. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY STATE, 2018-2027 (USD BILLION)
TABLE 16. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2018-2027 (USD BILLION)
TABLE 17. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, BY STATE, 2018-2027 (USD BILLION)
TABLE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY STATE, 2018-2027 (USD BILLION)
TABLE 19. UNITED STATES PULMONARY DRUGS MARKET: SCORES
TABLE 20. UNITED STATES PULMONARY DRUGS MARKET: BUSINESS STRATEGY
TABLE 21. UNITED STATES PULMONARY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 22. UNITED STATES PULMONARY DRUGS MARKET: RANKING
TABLE 23. UNITED STATES PULMONARY DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 24. UNITED STATES PULMONARY DRUGS MARKET: MERGER & ACQUISITION
TABLE 25. UNITED STATES PULMONARY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 26. UNITED STATES PULMONARY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 27. UNITED STATES PULMONARY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 28. UNITED STATES PULMONARY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 29. UNITED STATES PULMONARY DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

AstraZeneca plc
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co.
F.Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline plc
Mallinckrodt Pharmaceuticals
Merck & Co.
Novartis International AG
Pfizer Inc.
Sanofi S.A
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc